Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and available for distribution in Europe including Switzerland, and the UK. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.
Location: Switzerland, Vaud, Eysins
Employees: 201-500
Total raised: $16.2M
Founded date: 2007
Investors 2
| Date | Name | Website |
| - | Galen Part... | galen.com |
| - | Sophia Bus... | sophiabusi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.02.2013 | - | $5M | - |
| 06.03.2012 | - | $11.2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 03.02.2023 | Four Sure-Fire Ways To Become A Value Creator In Your Business Or Community | Manuel O. Méndez, Chief Executive Officer of Quotient Limited. |
| 24.05.2021 | QUOTIENT LIMITED Quotient Limited : Announces New $95 Million Financing Led by Highbridge | Transaction proceeds will be used to fund the further development of the MosaiQ platform beyond the Donor Lab and the commercial launch of MosaiQ JERSEY, Channel Islands, May 24, 2021 (GLOBE NEWSWIRE) -- Quotient Limited ("Quotient&quo... |
| 26.02.2013 | Quotient Biodiagnostics Raises Additional $5M | Quotient Biodiagnostics, a global transfusion diagnostics group, Raised an additional $5.0m in equity funding. Backers included Galen Partners and Paul Cowan, CEO and founding shareholder in Quotient. The company intends to use the funding ... |
| 06.03.2012 | Quotient Biodiagnostics Closes $11.2M Growth Equity Financing | Quotient Biodiagnostics Holdings Limited, a global transfusion diagnostics group, has completed an $11.2m growth equity financing. The round was led by Galen Partners, a US-based healthcare venture capital investment firm. The company inten... |
| 19.03.2010 | Haemonetics licenses Alba Bioscience blood typing reagents | Haemonetics Corp. (NYSE:HAE) inked a deal with Quotient Biodiagnostics Group subsidiary Alba Bioscience Ltd. that gives it exclusive access to Alba’s portfolio of blood-typing reagents. The Braintree, Mass.-based blood management products m... |